Humacyte, Inc. (HUMAW)Durham, United States | NasdaqGS
0.00 USD
0.00
(-78.049%) ⇩
(Aug. 25, 2026, 3:59 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 6:27 a.m. EDT
The security is effectively worthless and devoid of investment thesis. The price has collapsed to zero, trading at a fraction of a penny with no recent price history to analyze momentum. Fundamentally, the company is hemorrhaging cash with massive negative free cash flow and operating losses, while reporting negligible revenue. The balance sheet is precarious with debt significantly exceeding equity, and the return on equity is deeply negative. There is no dividend to speak of, and the lack of analyst coverage or institutional interest suggests the market has priced out any remaining value. This is a clear avoid. |
| Attribute | Value |
|---|---|
| Debt to Equity Ratio | 213.941 |
| Revenue per Share | 0.011 |
| Beta | 2.47 |
| Website | https://www.humacyte.com |
| Attribute | Value |
|---|---|
| Address1 | 2,525 East North Carolina Highway 54 |
| Ask | 0.1993 |
| Ask Size | 3 |
| Beta | 2.47 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 0.113 |
| City | Durham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.0009 |
| Current Ratio | 6.207 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.0039 |
| Day Low | 0.0009 |
| Debt To Equity | 213.941 |
| Ebitda | -103,228,000 |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -3.158 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.0039 |
| Fifty Two Week High Change | -0.003 |
| Fifty Two Week High Change Percent | -0.7692308 |
| Fifty Two Week Low | 0.0009 |
| Fifty Two Week Low Change | 0.0 |
| Fifty Two Week Low Change Percent | 0.0 |
| Fifty Two Week Range | 9.0E-4 - 0.0039 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,784,295,000,000 |
| Float Shares | 251,023,924 |
| Free Cashflow | -58,393,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 184 |
| Fullday Change | -0.0032000002 |
| Fullday Change Percent | -78.04878 |
| Fullday Price | 0.0009 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -79,374,000 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Language | en-US |
| Long Business Summary | Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina. |
| Long Name | Humacyte, Inc. |
| Market | us_market |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_107706507 |
| Net Income To Common | -96,668,000 |
| Open | 0.23 |
| Operating Cashflow | -97,193,000 |
| Operating Margins | -66.492615 |
| Phone | 919 313 9633 |
| Previous Close | 0.0041 |
| Price Hint | 4 |
| Price To Book | 0.007964602 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.367 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0032000002 |
| Regular Market Change Percent | -78.04878 |
| Regular Market Day High | 0.0039 |
| Regular Market Day Low | 0.0009 |
| Regular Market Day Range | 9.0E-4 - 0.0039 |
| Regular Market Open | 0.23 |
| Regular Market Previous Close | 0.0041 |
| Regular Market Price | 0.0009 |
| Regular Market Time | 1,787,687,990 |
| Regular Market Volume | 258,659 |
| Return On Assets | -0.49866 |
| Return On Equity | -5.47872 |
| Revenue Growth | 0.349 |
| Revenue Per Share | 0.011 |
| Sand P52 Week Change | 0.16207206 |
| Sector | |
| Sector Key | |
| Source Interval | 15 |
| State | NC |
| Symbol | HUMAW |
| Total Cash | 79,903,000 |
| Total Cash Per Share | 0.288 |
| Total Debt | 66,880,000 |
| Total Revenue | 2,121,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.158 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 258,659 |
| Website | https://www.humacyte.com |
| Zip | 27,713 |